ERA CONGRESS PARIS & VIRTUAL MAY 19-22, 2022 - FINAL PROGRAMME - European Renal Association
←
→
Page content transcription
If your browser does not render page correctly, please read the page content below
59 ERA
TH
CONGRESS
PARIS & VIRTUAL
MAY 19-22, 2022
FINAL
PROGRAMME
CONGRESS INFORMATION
Please click on the links below to see the content.
> GENERAL INFORMATION
> OPENING HOURS
> IMPORTANT ADDRESSES
> ERA COUNCIL MEMBERS
> CONGRESS SCIENTIFIC COMMITTEE
> PAPER SELECTION COMMITTEE & ABSTRACTS REVIEWERS 2
> BEST ABSTRACTS
Ten best abstracts
Eight best abstracts presented by young authors
Best abstracts presented by young authors
59 ERA
TH
CONGRESS
PARIS & VIRTUAL
MAY 19-22, 2022
Dear Colleagues, dear Friends,
The ERA Congress returns on site in 2022 after two years of fully virtual meetings due to the restrictions imposed by the Covid 19
pandemic. This year, the Congress will be hybrid with delegates in Paris or connected from their home Countries. This option will
allow all participants to attend one of the best medical Congresses in Europe, in whichever way they prefer.
The motto chosen for this year’s meeting is “Innovation, Prevention, Preparedness” that could summarise what we have
learned from the “Cov19 era”.
WELCOME Innovation, because medicine, particularly nephrology, needs constant innovation including new treatments and diagnostic tools.
Prevention, since it is essential to develop early detection based on new screening methodologies, and more effective and
personalized therapies.
ADDRESS Preparedness, as we need to be prepared to face all kinds of possible new problems such as new pandemics, influx of patients
fleeing their country due to unstable political situations and the resulting burden for health policy in a global world.
We constantly keep an eye on equity and ethics, as attested by the Welcome Lecture that will be presented by Valerie Luyckx on
May 19, entitled “Equity, sustainability, and ethics in kidney health”. This outstanding contribution will open the 59th ERA Congress
during the Welcome Ceremony.
The Scientific Committee, chaired by Annette Bruchfeld, worked very hard to provide the best programme taking also into
consideration gender balance, with fifty percent of invited speakers being female. She was supported by Maria José Soler, who
acted as the Chair of the Paper Selection Committee and by the Congress President, Pierre Ronco as well as by the two Congress
Secretaries, Denis Fouque and Ziad Massy.
Pierre Ronco, Signs of return to normality can also be seen from the large number of high-quality abstracts received from 76 countries.
Congress President The final version of the programme is the result of many hours of coordinated hard work among the Scientific Committee Chair,
the Congress President, the Paper Selecting Committee Chair, the Congress Secretaries and last but not least all the 3
ERA Headquarter Staff. A special thanks goes to the new staff members, Manuela Lorusso, David Simon, Federica Lo Cascio and
Gaston Chauchard.
On May 19, the first day of the Congress, in addition to the traditional CME and Hands-On Courses, a new Hands-On Course on
Renal Biopsy will be held. These tailored courses given by top European experts in the field and fully included in the Congress fee,
will offer a unique opportunity for professional development.
Another novelty this year are the Young Investigators Awards which from one have become three: the Rosanna Gusmano
Christoph Wanner Award (for young investigators in basic science), the Stanley Shaldon Award (for young investigators in translational science) and the
ERA President
Eberhard Ritz Award (for young investigators in clinical science). For the first time, these excellent young investigators will be offered
the opportunity to present their research topic in dedicated Plenary Lecture on May 22.
The programme will also include three new sessions: on-site Moderated Mini-Orals, Quick Fire 1, 2, 3 and the Fishbowl
Round Table.
These three sessions will be held in the Mini-Orals Hall in a very dynamic way.
Finally, the programme will be complemented by various interesting Industry Symposia.
We also would like to welcome all ERA Members to the ERA General Assembly, where our President and the Ex-Officio Officers
will update you on the work that has been done by our Society during the last year.
The hybrid format of the Congress will not only offer educational activities and top scientific content, but also innovative
networking opportunities: a new digital platform will enable all participants, including those who will be connected virtually, to
actively contribute to group discussions based on specific topics and communicate with other delegates on our Social Media Wall.
All delegates will be able to choose their favourite networking tools and join our international Community, sharing their knowledge
59 ERA
TH
and experience.
CONGRESS We are looking forward to welcoming you to the 59th ERA Congress!
PARIS & VIRTUAL
MAY 19-22, 2022
CONTENT &
DAILY INDEX
MODERATED INDUSTRY
SCIENTIFIC
MINI-ORALS & SPONSORED
PROGRAMME
QUICK FIRE 1,2,3 SYMPOSIA
THURSDAY - MAY 19, 2022 6 FRIDAY - MAY 20, 2022 53 FRIDAY - MAY 20, 2022 59
4
FRIDAY - MAY 20, 2022 13 SATURDAY - MAY 21, 2022 56 SATURDAY - MAY 21, 2022 67
SATURDAY - MAY 21, 2022 30
SUNDAY - MAY 22, 2022 47
59 ERA
TH
CONGRESS
PARIS & VIRTUAL
MAY 19-22, 2022
Mini-Oral
Sessions
Short pre-recorded presentations summarizing
the accepted abstracts in 5 minutes
59 ERA
TH
CONGRESS
PARIS & VIRTUAL
MAY 19-22, 2022
19 59 ERA
TH
DAY AT A CONGRESS
GLANCE PARIS & VIRTUAL
THU MAY 19-22, 2022
CME & HANDS-ON COURSES
CONTENT & CONGRESS OPENING 7
DAILY INDEX PRIMARY & SECONDARY GN, VASCULITIS AND AUTOIMMUNE DISEASES 7
HYPERTENSION, DIABETES, CARDIOVASCULAR DISEASES IN CKD 7
SCIENTIFIC PROGRAMME CKD AND BONE MINERAL DISORDERS IN CKD 7
HAEMO AND PERITONEAL DIALYSIS 8
THURSDAY - MAY 19, 2022 6
HANDS-ON COURSE ON RENAL BIOPSY 8
6
HANDS-ON COURSE ON ULTRASOUND OF ARTERIOVENOUS FISTULA 8
FRIDAY - MAY 20, 2022 13
HANDS-ON COURSE ON CATHETER PLACEMENT 8
KIDNEY TRANSPLANTATION 9
SATURDAY - MAY 21, 2022 30
BASICS OF GENETICS FOR NEPHROLOGIST 9
ACUTE KIDNEY INJURY 9
SUNDAY - MAY 22, 2022 47
ELECTROLYTES AND UROLITHIASIS 9
HANDS-ON COURSE ON ULTRASOUND OF ARTERIOVENOUS FISTULA 10
HANDS-ON COURSE ON CATHETER PLACEMENT 10
WELCOME CEREMONY + WELCOME LECTURE 11
19
THU
SCIENTIFIC PROGRAMME
HALL PLENARY 8:00-8:30 (CEST) HALL N01 08:45-12:20 (CEST) HALL N02 08:45-12:20 (CEST) HALL N03 08:45-12:20 (CEST)
CONGRESS OPENING CME 1 CME 2 CME 3
Welcome
PRIMARY & SECONDARY HYPERTENSION, DIABETES, CKD AND BONE MINERAL
Monica Fontana (ERA Executive Director), GN, VASCULITIS AND CARDIOVASCULAR DISEASES DISORDERS IN CKD
Italy AUTOIMMUNE DISEASES IN CKD
Chairs: Hanne Skou Jorgensen, Denmark
Congress facts & figures Chairs: Annette Bruchfeld, Sweden Chairs: Beatriz Fernandez Fernandez, Spain Sandro Mazzaferro, Italy
Maria Jose Soler (Chair of Paper Selection Kerstin Amann, Germany Pantelis Sarafidis, Greece Jelmer Humalda, Netherlands
Committee), Spain Andreas Kronbichler, United Kingdom Amaryllis Van Craenenbroeck, Belgium Introduction - setting the stage.
Most important Sessions to attend 1 Technical Challenges to Discover Novel A) CVD in CKD: Diagnosis Hanne Skou Jørgensen, DK
Annette Bruchfeld (Chair of Scientific Antigens and Autoantibodies in Minimal 1 Cardiovascular risk screening in CKD: 1 Bone loss in the era of steroid-sparing
Committee), Sweden Change Disease and Membranous biomarkers, cardiac MRI, cardiac US. immunosuppressive protocols.
Congress official opening Nephropathy. Patrick Mark, United Kingdom Martine Cohen-Solal, France
Christoph Wanner (ERA President), Germany Astrid Weins, USA 2 Cardiovascular risk screening in CKD: 2 Renal osteodystrophy post-transplant –
2 Immunosuppressive Therapy in Patients blood pressure monitoring. lessons from bone biopsy studies.
with IgA Nephropathy revisited – clinical Michael Doumas, Greece Nathalie Bravenboer, Netherlands
and histological aspects. 7
3 Cardiovascular risk screening in CKD: 3 Mineral metabolism and acid-base
Jürgen Floege, Germany and Kerstin endothelial function (methods) and arterial disturbances.
Amann, Germany stiffness. Jelmer Humalda, Netherlands
3 Repeat kidney biopsy as a biomarker in Marietta Theodorakopoulou, Greece
vasculitis and other GNs. 4 Optimizing cardiovascular health post-
B) CVD in CKD: Treatment transplant.
Ingeborg Bajema, Netherlands 1 HF with pEF in CKD: the cardiology Marc Vervloet, Netherlands
4 Hematologic Disorders and Kidney perspective...
Disease. Anne-Catherine Pouleur, France 5 Optimizing bone health post-transplant.
Tiffany Caza, USA Pieter Evenepoel, Belgium
2 HF with pEFIN CKD: the nephrology
5 Does Covid-19 or SARS-Cov-2 vaccine perspective. Summary and concluding remarks.
induce kidney disease? Jolanta Malyszko, Poland Sandro Mazzaferro, Italy
Annette Bruchfeld, Sweden 3 The role of lifestyle, exercise and
6 Comorbidities in ANCA-Associated rehabilitation in cardiorenal patient.
Vasculitis. Sharlene Greenwood, United Kingdom
Andreas Kronbichler, United Kingdom C) CVD in CKD: Collaboration
Perspectives
Achieving the best strategy for ESRD patients
creating combined cardiorenal units.
Jose Luis Gorriz, Spain
19 THU
59 ERA
TH
CONGRESS
PARIS & VIRTUAL
MAY 19-22, 2022
19
THU
SCIENTIFIC PROGRAMME
HALL N04 08:45-12:20 (CEST) HALL S01 08:45-15:00 (CEST) HALL S02 08:45-12:20 (CEST) HALL S03 08:45-12:20 (CEST)
CME 4 HANDS-ON COURSE ON RENAL HANDS-ON COURSE HANDS-ON COURSE ON
HAEMO AND PERITONEAL BIOPSY ON ULTRASOUND OF CATHETER PLACEMENT
DIALYSIS ARTERIOVENOUS FISTULA This course will be done using Palindrome
Chairs: Kate Stevens, United Kingdom ™catheter family; please considered that
Chairs: Rukshana Shroff, United Kingdom Maurizio Gallieni, Italy Chairs: Josè Ibeas, Spain similar products from other companies are
Mehmet Kanbay, Turkey Tamara Jemcov, Serbia available on the market
Trainers: Stefanie Mayer, Germany
Karlien François, Belgium Roberta Miglio, Italy N-Path introduction Chairs: Maria Guedes, Portugal
Dialysis: physiology and pathology Michele Rossini, Italy Josè Ibeas, Spain Sokratis Stoumpos, United Kingdom
1 Preserving residual kidney function in Alessandra Pesino, Italy
1 Introduction
dialysis patients. Jennifer Lees, United Kingdom Trainers: Lucile Mercadal, France
Josè Ibeas, Spain
Mehmet Kanbay, Turkey Fulvio Fiorini, Italy
N-Path introduction Tamara Jemcov, Serbia
Kaitlin Mayne, United Kingdom
2 Dialysis adequacy in PD and HD. Loreto Gesualdo, Italy 2 Non-maturing arteriovenous fistula Akoha Mauriac, France
Giorgina Piccoli, Italy Tamara Jemcov, Serbia
1 Introduction
3 Understanding peritoneal membrane N-Path introduction
Emily McQuarrie, United Kingdom, 3 How to examine a vascular access
physiology - clinical implications. Maurizio Gallieni, Italy
Kai Loapu, Germany Jernej Pajek, Slovenia
Johann Morelle, Switzerland 1 Introduction 8
2 Indications and epidemiology of native
Round table discussion Procedure / Virtual simulation Maria Guedes, Portugal
kidney biopsy
1 Virtual reality demo. From mapping to Sokratis Stoumpos, United Kingdom
Dialysis - technology Colin Geddes, United Kingdom
1 Renal replacement therapies in natural surveillance 2 Central vein stenosis
3 Practical pathology for Biopsy (Processing
disasters and pandemics. Jose Ibeas, Spain Pete Thomson, United Kingdom
of the samples and tests)
Carlo Basile, Italy Candice Roufosse, United Kingdom 2 Vein mapping 3 Fibrin sheath
2 Home or institutional haemodialysis? Jernej Pajek, Slovenia Sokratis Stoumpos, United Kingdom
4 Practical pathology for Biopsy (Processing
Helena Rydell, Sweden of the samples and tests) 3 Stenosis 4 Kinking and tip position
3 Is citrate-based dialysate the future? Candice Roufosse, United Kingdom Jose Ibeas, Spain Maria Guedes, Portugal
Karlien François, Belgium Q&A and Discussion 4 Thrombosis 5 Atrial thrombus
Round table discussion Marius Kusztal, Poland Carlo Lomonte, Italy
Procedure / Virtual simulation
Dialysis at the extremes of age 5 Discussion Procedure / Virtual simulation
1 Concluding remarks
1 Pediatrics - what adult nephrologists Emily McQuarrie, United Kingdom,
should know about pediatric dialysis. Kai Loapu, Germany
Rukshana Shroff, United Kingdom
2 Geriatric patients - when to start
dialysis and modality selection.
Sandip Mitra, United Kingdom
19 THU
Discussion
59 ERA
TH
CONGRESS
PARIS & VIRTUAL
MAY 19-22, 2022
19
THU
SCIENTIFIC PROGRAMME
HALL N01 13:00-16:40 (CEST) HALL N02 13:00-16:40 (CEST) HALL N03 13:00-16:40 (CEST) HALL N04 13:00-16:40 (CEST)
CME 5 CME 8 CME 6 CME 7
KIDNEY TRANSPLANTATION BASICS OF GENETICS FOR ACUTE KIDNEY INJURY ELECTROLYTES AND
NEPHROLOGISTS UROLITHIASIS
Chairs: Marta Crespo, Spain Chairs: Valerie Luycks, Switzerland
Christophe Mariat, France Chairs: Emilie Cornec Le Gal, France Vincenzo Cantaluppi, Italy Chairs: Olivier Bonny,
Jasper Callemeyn, Belgium Roser Torra, Spain Turgay Saritas, Germany Ewout Hoorn,
1 Untangling the cause of transplant failure Lucille Figueres, France 1 Novel diagnostic approaches in AKI: from Jean-Philippe Bertocchio, Netherlands
Klemens Budde, Germany 1 What should I know before ordering a urine analysis to machine learning 1 Hyponatremia: new diagnostic and
genetic test? Eric Hoste, Belgium therapeutic developments.
2 Management of chronic kidney disease
after transplantation Beata Lipska, Poland 2 Management of AKI- fluids, Mirjam Christ-Crain, Switzerland
Anne-Elisabeth Heng, France 2 Prescribing a genetic test: when, how, catecholamine, diuretics, ultrafiltration 2 Hypomagnesemia: from common causes to
and what should be discussed with your Marlies Ostermann, United Kingdom rare diseases.
3 Immunosuppressive treatment after kidney
transplant failure patients before and after? 3 Organ system crosstalk in AKI Tom Nijenhuis, Netherlands
María José Pérez-Sáez, Spain Emilie Cornec Le Gal, France Faeq Husain-Syed, Germany 3 The return of an old friend: thiazide
4 Impact of sensitization and HLA matching 3 What are the reproductive options that can 4 Nutrition in AKI diuretics in CKD and kidney stones.
on repeat transplantation be offered? Alice Sabatino, Italy Daniel Fuster, Switzerland 9
Aleksandar Senev, Belgium Rozemarijn Snoek, Netherlands
5 Nephrotoxicity of novel cancer drugs 4 Metabolic acidosis and citrate in CKD and
5 Prognosis of the repeat transplantation 4 How frequent are genetic diseases as Angel L M de Francisco, Spain kidney stones.
Umberto Maggiore, Italy cause of CKD? Sandrine Lemoine, France
Roser Torra, Spain
5 Oxalate in nephrology: emerging roles
5 Making inherited tubulopathies easy and interventions.
Lucille Figueres, France Emmanuel Letavernier, France
6 Practical session about inherited kidney
diseases
Daniel Gale, United Kingdom
19 THU
59 ERA
TH
CONGRESS
PARIS & VIRTUAL
MAY 19-22, 2022
19
THU
SCIENTIFIC PROGRAMME
HALL S02 13:00-16:40 (CEST) HALL S03 13:00-16:40 (CEST)
HANDS-ON COURSE HANDS-ON COURSE ON
ON ULTRASOUND OF CATHETER PLACEMENT
ARTERIOVENOUS FISTULA This course will be done using Palindrome
™catheter family; please considered that
Chairs: Josè Ibeas, Spain similar products from other companies are
Tamara Jemcov, Serbia available on the market
N-Path introduction Chairs: Maria Guedes, Portugal
Josè Ibeas, Spain Sokratis Stoumpos, United Kingdom
1 Introduction
Trainers: Lucile Mercadal, France
Josè Ibeas, Spain
Fulvio Fiorini, Italy
2 Non-maturing arteriovenous fistula Kaitlin Mayne, United Kingdom
Tamara Jemcov, Serbia Akoha Mauriac, France
3 How to examine a vascular access N-Path introduction
Jernej Pajek, Slovenia Maurizio Gallieni, Italy
Procedure / Virtual simulation 1 Introduction 10
1 Virtual reality demo. From mapping to Maria Guedes, Portugal
surveillance Sokratis Stoumpos, United Kingdom
Jose Ibeas, Spain 2 Central vein stenosis
2 Vein mapping Pete Thomson, United Kingdom
Jernej Pajek, Slovenia 3 Fibrin sheath
3 Stenosis Sokratis Stoumpos, United Kingdom
Jose Ibeas, Spain 4 Kinking and tip position
4 Thrombosis Maria Guedes, Portugal
Marius Kusztal, Poland 5 Atrial thrombus
Carlo Lomonte, Italy
Procedure / Virtual simulation
19 THU
59 ERA
TH
CONGRESS
PARIS & VIRTUAL
MAY 19-22, 202219
THU
SCIENTIFIC PROGRAMME
HALL PLENARY 17:00-18:15 (CEST)
WELCOME CEREMONY +
WELCOME LECTURE
> Research excellence in 6 Introduction to the
1 Welcome words nephrology (clinical or Welcome Lecture
Pierre Ronco, Congress basic science): Annette Bruchfeld,
President Andreas Linkermann Sweden
> Rosanna Gusmano Award 7 Welcome Lecture
2 Presidential address (for young investigators “Equity, sustainability, and
Christoph Wanner, ERA in basic science): ethics in kidney health”
President Turgay Saritas Valerie Luyckx, Switzerland
11
3 Diploma and thanks > Stanley Shaldon Award
Christoph Wanner to Annette Bruchfeld, (for young investigators
Chair of the SC in translational science):
Francesco Trepiccione
4 ERA Awards
> ERA Awards for > Eberhard Ritz Award
Outstanding Clinical (for young investigators
Contribution: in clinical science):
Ziad Massy Jennifer Lees
> Outstanding Basic
Science Contributions 5 Honorary
to Nephrology: Membership
Corinne Antignac Andrew Levey
19 THU
59 ERA
TH
CONGRESS
PARIS & VIRTUAL
MAY 19-22, 2022Stay updated on the latest
trends in Nephrology
Exclusive for ERA Members: Hot Topics in Nephrology created
by our Working Groups, EACCME ® accreditation included20 59 ERA
TH
DAY AT A CONGRESS
GLANCE PARIS & VIRTUAL
FRI MAY 19-22, 2022
INNOVATIONS IN PATHOLOGY TO SUPPORT NEPHROLOGISTS 16
CONTENT & RENAL AND CARDIAC PROTECTION IN DIABETIC AND NON-DIABETIC CKD 16
DAILY INDEX HEART AND KIDNEY: AN INSIDIOUS RELATIONSHIP 16
ERA REGISTRY 16
SCIENTIFIC PROGRAMME
TRANSPLANTATION BASIC SCIENCE 17
INHERITED CYSTIC AND TUBULOINTERSTITIAL NEPHROPATHIES: NEW
THURSDAY - MAY 19, 2022 6 17
GENES, NEW MECHANISMS, NEW THERAPIES
DIAGNOSTIC TOOLS FOR AKI AND MANAGEMENT 17 13
FRIDAY - MAY 20, 2022 13 PERITONEAL DIALYSIS FROM BENCH TO BEDSIDE 17
BEYOND THE BASICS OF SOCIAL MEDIA USE: ADVANCED SOCIAL
18
MEDIA TOOLS FOR EDUCATION
SATURDAY - MAY 21, 2022 30 VARIOUS ASPECTS OF CELL BIOLOGY & METABOLISM II 18
PLENARY LECTURE 1 19
SUNDAY - MAY 22, 2022 47 LATE BREAKING CLINICAL TRIALS 19
PHYSICAL ACTIVITIES IN CKD PATIENTS 20
CKD ARRHYTHMIAS AND ANTICOAGULATION 20
DIGNOSTICS AND THERAPEUTIC ADVANCES IN PEDIATRIC NEPHROLOGY 20
HISTOPATHOLOGY AND BEYOND IN RENAL TRANSPLANTATION 20
NOVEL TECHNIQUES - NOVEL INSIGHTS INTO KIDNEY FUNCTION 2120 59 ERA
TH
DAY AT A CONGRESS
GLANCE PARIS & VIRTUAL
FRI MAY 19-22, 2022
CLASSIFICATION OF CHRONIC KIDNEY DISEASE 21
CONTENT & CLINICAL ASPECTS OF TUBULAR TRANSPORT PATHOLOGY 21
DAILY INDEX NEW DIAGNOSTIC AND PROGNOSTIC TOOLS IN IGAN 21
NOVEL TOOLS FOR TRANSPLANT OUTCOME PREDICTION 22
SCIENTIFIC PROGRAMME
JOINT SYMPOSIA ERA- SFNDT ARTIFICIAL INTELLIGENCE IN NEPHROLOGY 23
GENETICS PLUS X: INNOVATION FROM COMBINING TECHNOLOGIES 23
THURSDAY - MAY 19, 2022 6
ASSESSING QUALITY OF DIALYSIS DELIVERY 23 14
DRUG DISCOVERY AND REPURPOSING 23
FRIDAY - MAY 20, 2022 13
COVID, AKI AND BEYOND 24
KIDNEY GRAFT LOSS - IS IT INEVITABLE? 24
SATURDAY - MAY 21, 2022 30
METABOLIC KIDNEY INJURY 24
RECENT ADVANCES IN THE TREATMENT OF IGAN 24
SUNDAY - MAY 22, 2022 47
CHALLENGES IN PEDIATRIC NEPHROLOGY 25
RISK FACTORS IN CKD 25
SGLT2I IN CKD FISHBOWL SESSION NEW 25
WHY NEPHROLOGY NEEDS ADVANCED STATISTICAL METHODS 26
PREVENTION OF CKD PROGRESSION - NEWS IN THE TRADITIONAL
26
RISK FACTORS20 59 ERA
TH
DAY AT A CONGRESS
GLANCE PARIS & VIRTUAL
FRI MAY 19-22, 2022
PLASTICITY OF RENAL CELLS 26
CONTENT & UPCOMING INNOVATIONS IN ACUTE KIDNEY INJURY 26
DAILY INDEX CLINICAL OUTCOMES IN TRANSPLANTATION 27
PATHOPHYSIOLOGY OF THE GLOMERULUS 27
SCIENTIFIC PROGRAMME
NEW ADVANCES IN LUPUS NEPHROPATHY 27
NEW INSIGHTS FROM CLINICAL TRIALS IN ANCA-ASSOCIATED VASCULITIS 27
THURSDAY - MAY 19, 2022 6
ASN HIGHLIGHTS 28 15
FRAILTY AND DIALYSIS COMPLICATIONS 28
FRIDAY - MAY 20, 2022 13
SATURDAY - MAY 21, 2022 30
SUNDAY - MAY 22, 2022 4720
FRI
SCIENTIFIC PROGRAMME
HALL PLENARY 08:00-09:30 (CEST) HALL N01 08:00-09:30 (CEST) HALL N02 08:00-09:30 (CEST) HALL N03 08:00-09:30 (CEST)
Symposium 3.1 Symposium 4.1 Symposium 7.1 Symposium 0.2
INNOVATIONS IN PATHOLOGY RENAL AND CARDIAC HEART AND KIDNEY: AN ERA REGISTRY ETHICS ERAC YNP
TO SUPPORT NEPHROLOGISTS PROTECTION IN DIABETIC AND INSIDIOUS RELATIONSHIP
European
Renal Association Curatorium Young Nephrologists’ Platform
Chairs: Kitty J. Jager, Netherlands REGISTRY NPPC ERBP
NON-DIABETIC CKD
Nephrology
European Renal Best Practice
and Public Policy Committee
Chairs: Ingeborg M. Bajema, Netherlands Chairs: Beatriz Fernandez Fernandez, Spain Alberto Ortiz, Spain GNC
Green Nephrology Committee
SAB
Scientific Advisory Board
ECC
Electronic
Communication Committee
Jan Ulrich Becker, Germany Chairs: Maria José Soler Romeo, Spain Mehmet Kanbay, Turkey 1 Results of the European transplant survey:
1 Remote renal pathology counseling: Davide Bolignano, Italy 1 Lung congestion in chronic kidney failure initiatives and barriers affecting kidney
Opportunites for the clinician Carmine Zoccali, Italy transplant rates
ETHICS ERAC YNP
1 SGLT2 inhibitors: from bench to bedside European
Renal Association Curatorium Young Nephrologists’ Platform
Helen Liapis, Greece for patients with cardiorenal disease Rianne Boenink, Netherlands REGISTRY NPPC ERBP
2 The importance of screening and Nephrology
and Public Policy Committee
European Renal Best Practice
2 Digital Data-Driven Kidney Pathology Daniël van Raalte, Netherlands assessment of kidney function in patients 2 Mortality due to malignancies in children
GNC
Green Nephrology Committee
SAB
Scientific Advisory Board
ECC
Electronic
Communication Committee
Assessment 2 Novel mineralocorticoid receptors with heart failure and DMT2 starting kidney replacement therapy after
Arvydas Laurinavicius, Lithuania antagonists: an update of mechanisms and Martin De Borst, Netherlands cancer therapy
recent trials Henna Puusaari, Finland
3 Artificial intelligence-augmented digital 3 Uraemic Cardiomyopathy – is it truly
nephropathology Frederik Persson, Copenhagen reversible by transplantation? 3 Effect of dialysis initiation on health-
Peter Boor, Aachen, Germany 3 New kidney protective drugs: how do they Charles Ferro, United Kingdom related quality of life and symptoms in
impact the guidelines? older patients 16
Paola Fioretto, Italy Esther de Rooij, Netherlands
20 FRI
59 ERA
TH
CONGRESS
PARIS & VIRTUAL
MAY 19-22, 202220
FRI
SCIENTIFIC PROGRAMME
HALL N04 08:00-09:30 (CEST) HALL S01 08:00-09:30 (CEST) HALL S02 08:00-09:30 (CEST) HALL S03 08:00-09:30 (CEST)
Symposium 6.3 Symposium 2.6 Free Communication Session 34 Free Communication Session 24
TRANSPLANTATION BASIC INHERITED CYSTIC AND + Mini Lectures + Mini Lectures
SCIENCE TUBULOINTERSTITIAL DIAGNOSTIC TOOLS FOR AKI PERITONEAL DIALYSIS FROM
NEPHROPATHIES: NEW GENES, AND MANAGEMENT BENCH TO BEDSIDE
Chairs: Daniel Abramowicz, Belgium
NEW MECHANISMS, NEW
Maria C. Haller, Germany Chairs: Christiane Erley, Germany Chairs: Van Biesen, Belgium
THERAPIES
1 Single cell technology; the role of the Ben Sprangers, Belgium
ML: Jernej Pajek, Slovenia
immune cell atlas in renal transplantation Chairs: Marianne Verhaar, Netherlands
ML: Nicolas Selby, United Kingdom CHALLENGES IN TRAINING
Menna Clatworthy, United Kingdom Ron Gansevoort, Norway
NEPHROLOGISTS FOR HOME
1 The expanding genetic spectrum of DEVELOPING AN AKI ALERT SYSTEM ORIENTED CARE
2 Getting the most out of your data using ACUTE KIDNEY INJURY AND EXPOSURE
artificial intelligence: from bench to polycystic kidney and liver diseases
Emilie Cornec-Le Gall, France TO NEPHROTOXIC DRUGS IN CRITICALLY
bedside in transplantation. Or how to talk ILL PATIENTS: A REPORT FROM THE
to molecular biologists? 2 Unravelling diseases mechanisms in MOLECULAR AND FUNCTIONAL
MULTICENTER RESCUE PROJECT IN THE
Germaine Wong, Australia ciliopathies CHARACTERIZATION OF THE MESOTHELIAL
NETHERLANDS
Sophie Saunier, Paris AND ENDOTHELIAL CELL BARRIER IN
3 ABMR in the absence of anti-HLA DSAs Izak Yasrebi-de Kom, Netherlands
HEALTH, CKD AND PERITONEAL DIALYSIS
Maarten Naesens, Belgium 3 New therapeutic approaches for toxic 17
NOVEL GLUCOSE-LOWERING DRUGS Iva Marinovic, Germany
proteinopathies, the example of AND THE RISK OF ACUTE KIDNEY INJURY
ADTKD-MUC1 THE ABSENCE OF STING PREVENTS
IN ROUTINE CARE; THE STOCKHOLM
Moran Dvela-Levitt, Israel PERITONEAL DAMAGE IN A MURINE
CREATININE MEASUREMENTS (SCREAM)
MODEL OF PERITONEAL FIBROSIS
PROJECT
Vanessa Marchant, Chile
Jim Alkas, Sweden
STEVIA AS AN ALTERNATIVE OSMOTIC
STOPPING VERSUS CONTINUING
AGENT FOR PERITONEAL DIALYSIS FLUID
RENIN-ANGIOTENSIN SYSTEM INHIBITORS
Valeria Kopytina, Spain
AFTER ACUTE KIDNEY INJURY AND
ADVERSE CLINICAL OUTCOMES; AN CHANGES IN THE GUT MICROBIOME
OBSERVATIONAL STUDY FROM ROUTINE AND SYSTEMIC METABOLOME IN AN IN
CARE DATA VIVO MODEL OF PERITONEAL DIALYSIS
Roemer Janse, Netherlands SUPPLEMENTED WITH ALANYL-GLUTAMINE
Robin Hoogenboom, Austria
ML: Stephane Gaudry, France
ONGOING AND RECENT CLINICAL TRIALS
IN AKI
20 FRI
59 ERA
TH
CONGRESS
PARIS & VIRTUAL
MAY 19-22, 202220
FRI
SCIENTIFIC PROGRAMME
VIRTUAL HALL 1 08:00-09:30 (CEST) VIRTUAL HALL 2 08:00-09:30 (CEST)
Symposium 0.6 Free Communication Session 8
BEYOND THE BASICS OF + Mini Lectures
SOCIAL MEDIA USE: ADVANCED VARIOUS ASPECTS OF CELL
SOCIAL MEDIA TOOLS FOR BIOLOGY & METABOLISM II
EDUCATION
Chairs: Maria Eriksson Svensson, Sweden
Chairs: Kate Stevens, United Kingdom Carsten Wagner, Switzerland
Alexander Rosenkranz, Austria
1 Creating and distributing Visual Abstracts Sophie de Seigneux, France
Menna Clatworthy, United Kingdom Renal gluconeogenesis as a novel target to
reduce mortality in AKI
2 Polarization: Morphology of Renal
Networks on Twitter PHYSIOLOGICAL ROLE OF KV
Tejas Desaim, USA CHANNEL IN URETER SMOOTH MUSCLE
CELL INVESTIGATED QUANTITATIVELY BY
3 Generating data from Social Media: a tool ELECTROPHYSIOLOGICAL MODELING
to be taken seriously? Chitaranjan Mahapatra, India
Kate Stevens, United Kingdom 18
CHRONIC HIGH PHOSPHATE LEVEL
IMPAIRS CARDIAC HEALTH
Andrea Grund, Germany
URIC ACID STIMULATES CYTOSKELETON
PATHWAYS IN VASCULAR SMOOTH
MUSCLE CELLS THROUGH F-ACTIN
POLYMERIZATION AND ATROGIN, ASMA
AND SM22 UP REGULATION
Elisa Russo, Italy
CHARACTERIZATION OF ADIPOCYTE
SIZE AND GLUCOSE UPTAKE IN ADIPOSE
TISSUE WITH FOCUS ON DIFFERENT
PERIRENAL FAT DEPOTS
Maria Eriksson Svensson, Sweden
20 FRI
59 ERA
TH
CONGRESS
PARIS & VIRTUAL
MAY 19-22, 202220
FRI
SCIENTIFIC PROGRAMME
HALL PLENARY 10:45-11:30 (CEST) HALL PLENARY 11:45-13:15 (CEST)
PLENARY LECTURE 1 Symposium 0.1
Chairs: Pierre Ronco, France LATE BREAKING CLINICAL TRIALS
Francesca Mallamaci, Italy Chairs: Maria Jose Soler Romeo, Spain
Danilo Fliser, Germany
PCSK9: a journey of
discovery from genetics 1 EFFECTS OF ASPIRIN IN PRIMARY
to clinical trials PREVENTION OF CARDIOVASCULAR
Catherine Boileau, France (CV) DISEASE IN PEOPLE WITH CHRONIC
KIDNEY DISEASE (CKD): RESULTS OF THE
TIPS3 TRIAL
Johannes F.E. Mann, Germany
2 THE THOMAS STUDY (TOWARDS HOME-
BASED ALBUMINURIA SCREENING): A
RANDOMIZED STUDY INVESTIGATING
TWO STRATEGIES FOR EARLY DETECTION
AND TREATMENT OF CHRONIC KIDNEY 19
DISEASE
Ronald Gansevoort, Netherlands
3 IMPACT OF ALKALI THERAPY ON EGFR
IN KIDNEY TRANSPLANT RECIPIENTS
(PRESERVE-TRANSPLANT STUDY;
NCT03102996)
Nilufar Mohebbi, Switzerland
4 URINARY DKK3 PREDICTS SHORT-TERM
EGFR DECLINE AND NEPHROPROTECTIVE
EFFICACY OF ANTIHYPERTENSIVE THERAPY
IN CHILDREN WITH CKD
Franz Schaefer, Germany
5 PATIROMER FOR THE MANAGEMENT
OF HYPERKALEMIA IN HEART FAILURE
PATIENTS WITH REDUCED EJECTION
FRACTION RECEIVING RENIN-
ANGIOTENSIN-ALDOSTERONE
SYSTEM INHIBITORS: RESULTS FROM A
PRESPECIFIED ANALYSIS BY EGFR FROM
THE DIAMOND TRIAL
20 FRI
Patrick Rossignol, France
59 ERA
TH
6 BIO-IMPEDANCE SPECTROSCOPY (BIS) TO
PRESERVE RESIDUAL KIDNEY FUNCTION
CONGRESS (RKF) IN INCIDENT HAEMODIALYSIS (HD)
PATIENTS: RESULTS OF THE BISTRO TRIAL
PARIS & VIRTUAL Simon Davies, United Kingdom
MAY 19-22, 202220
FRI
SCIENTIFIC PROGRAMME
HALL N01 11:45-13:15 (CEST) HALL N02 11:45-13:15 (CEST) HALL N03 11:45-13:15 (CEST) HALL N04 11:45-13:15 (CEST)
Symposium 7.3 Symposium 5.1 Symposium 2.1 Symposium 6.4
PHYSICAL ACTIVITIES IN CKD CKD ARRHYTHMIAS AND DIGNOSTICS AND THERAPEUTIC HISTOPATHOLOGY AND
PATIENTS ANTICOAGULATION ADVANCES IN PEDIATRIC BEYOND IN RENAL
NEPHROLOGY TRANSPLANTATION
Chairs: Jonathan Gabriel Fox, United Chairs: Mario Cozzolino, Italy
Kingdom Nada Dimkovic, Serbia Chairs: Emilie Cornec Le Gal, France
Chairs: Bruno Watschinger, Austria
Sebastjan Bevc, Slovenia Nine Knoers, Netherlands
1 Arrhythmias and heart failure in CKD Z. Serhan Tuglular, Turkey
1 Surveying Physical activity in CKD and ESKD 1 Novel immunosuppression strategies in
1 Determinants of early graft loss: what can
patients: what Nephrologists should know. Karolina Szummer, Sweden kidney transplantation
we learn from histopathological findings?
Amaryllis Van Craenenbroeck, Belgium Lars Pape, Hannover, Germany
2 Anticoagulation in patients with CKD and Marlies Reinders, Netherlands
2 Physical exercise in CKD patients: when ESKD 2 Innovative therapies for nephrotic
2 The importance of electron microscopy
and how is it feasible?Germaine Wong, Marie Evans, Sweden syndrome
in diagnosing renal transplant rejection
Australia Marina Vivarelli, Italy
3 Sudden death in patients with ESKD Candice Roufosse, United Kingdom
Naomi Clyne, Sweden 3 Mitochondrial diseases from childhood to
Nobuhiko Joki, Japan 3 MicroRNA and Chemokine Profiles in
3 Assessment and management of obesity adulthood
Urine to Identify renal transplant rejection 20
and metabolic syndrome in children with Fatih Ozaltin, Turkey
Michael Eikmans, Netherlands
CKD and after kidney transplantation
Stella Stabouli, Greece
20 FRI
59 ERA
TH
CONGRESS
PARIS & VIRTUAL
MAY 19-22, 202220
FRI
SCIENTIFIC PROGRAMME
HALL S01 11:45-13:15 (CEST) HALL S02 11:45-13:15 (CEST) HALL S03 11:45-13:15 (CEST) VIRTUAL HALL 1 11:45-13:15 (CEST)
Symposium 1.1 Free Communication Session 21 Free Communication Session 4 Free Communication Session
NOVEL TECHNIQUES - NOVEL + Mini Lectures + Mini Lectures 13 + Mini Lectures
INSIGHTS INTO KIDNEY CLASSIFICATION OF CHRONIC CLINICAL ASPECTS OF TUBULAR NEW DIAGNOSTIC AND
FUNCTION KIDNEY DISEASE TRANSPORT PATHOLOGY PROGNOSTIC TOOLS IN IGAN
Chairs: Giovambattista Capasso, Italy Chairs: Catalina Martin, Spain Chairs: Sydney Tang, Hong Kong
Valerie A. Luyckx, Switzerlands Chairs: Giovanni Gambaro, Italy
Stephen Walsh, United Kingdom Sandrine Florquin, Netherlands
Inagi Reiko, Japan
1 Urinary extracellular vesicles and tubular ML: Maarten Rookmaaker, Netherlands
transport ML: Fernando Caravaca-Fontán, Spain
THE DIFFERENT FACES OF 'THE' RENAL ML: Michael Straub, Germany
Ewout J Hoorn, Netherlands TREATMENT DURATION AND EFFICACY IN
FUNCTION: LOOKING BEYOND THE MEDULLARY SPONGE KIDNEY AND RTA -
C3 GLOMERULOPATHY
2 Pathogenic evaluation of synonymous NORMALIZED EGFR FOR DRUG DOSING, A CHALLENGE AT THE NEPHROLOGY AND
COL4A5 variants in X-linked Alport PROGNOSTICATION AND FOLLOW UP. UROLOGY JUNCTION POPULATION-BASED IDENTIFICATION
syndrome using a minigene assay. OF BIOPSY PROVEN IGA NEPHROPATHY
CYSTATIN C TESTING IMPROVES RISK
Tomoko Horinouchi, Japan USING NATURAL LANGUAGE
STRATIFICATION ASSOCIATED WITH
MULTICENTRIC EXPERIENCE WITH PROCESSING: THE KNIGHT STUDY
CHRONIC KIDNEY DISEASE WITHOUT
RNA INTERFERENCE MEDICATION Alan Go, USA 21
ADOPTING AGE-ADAPTED DIAGNOSTIC
THRESHOLDS: A UK BIOBANK STUDY (OXLUMO®) IN PATIENTS WITH PRIMARY AUTOMATED MEST-C CLASSIFICATION
3 2-Photon microscopy and Cell-fate Jennifer Lees, United Kingdom HYPEROXALURIA TYPE 1 IN IGA NEPHROPATHY USING DEEP-
tracking reveals novel repair mechanisms Bernd Hoppe, Germany LEARNING BASED SEGMENTATION
IMPACT OF REMOVING RACE FROM
in kidney injury Elise Marechal, France
THE CKD-EPI EQUATION: ANALYSIS OF 1.6 EFFECT OF URINE ALKALINAZATION ON
Ina Schiessl, Denmark
MILLION SWEDISH ADULTS URINARY INFLAMMATORY MARKERS RNA SEQUENCING OF MICRODISSECTED
Edouard Fu, Netherlands ANALYZED BY MASS SPECTROMETRY IN KIDNEY BIOPSIES FROM IGA
PATIENTS WITH CYSTINURIA NEPHROPATHY PATIENTS
THE RACE-FREE EGFR EQUATION, THE
Caroline Prot-Bertoye, France Anna Levin, Sweden
KIDNEY FAILURE RISK EQUATION AND
REFERRALS TO SPECIALIST RENAL CLINICS URINARY LITHOGENIC PROFILE IN NEW TOOL TO PREDICT THE CLINICAL
Michael Sullivan, United Kingdom PATIENTS WITH NON-ALCOHOLIC FATTY COURSE AND RENAL FAILURE IN
A SYSTEMS NEPHROLOGY FRAMEWORK LIVER DISEASE PATIENTS WITH IMMUNOGLOBULIN A
FOR THE MOLECULAR CLASSIFICATION OF Matteo Bargagli, Italy NEPHROPATHY.
CHRONIC KIDNEY DISEASE SHEAR WAVE ELASTOGRAPHY EFFECTIVE Francesco Paolo Schena, Italy
Tobias Bohnenpoll, Germany IN ULTRASOUND DIAGNOSIS OF
CHRONIC KIDNEY DISEASE IN PATIENTS
WITH HYPERURICEMIA AND GOUT
Rostyslav, Ukraine
20 FRI
59 ERA
TH
CONGRESS
PARIS & VIRTUAL
MAY 19-22, 202220
FRI
SCIENTIFIC PROGRAMME
VIRTUAL HALL 2 11:45-13:15 (CEST)
Free Communication Session
28 + Mini Lectures
NOVEL TOOLS FOR
TRANSPLANT OUTCOME
PREDICTION
Chairs: My Svensson, Norway
Alexander Rosenkranz, Austria
ML: Annemarie Weissenbacher, Austria
TAILORING IMMUNOSUPPRESSION:
LESSONS FROM THE IMMUNOLOGY LAB.
MULTIDIMENSIONAL
PROGNOSTICATION TOOL FOR KIDNEY
TRANSPLANT PATIENT SURVIVAL: THE
MORTALITY MBOX. 22
Charlotte Debiais-Deschamps, France
OF THE OPTIMAL TORQUE TENO VIRUS
RANGE FOR RISK STRATIFICATION OF
GRAFT REJECTION AND INFECTION IN
KIDNEY TRANSPLANT RECIPIENTS BY TTV
R-GENE®
Frederik Haupenthal, Austria
DEVELOPMENT AND VALIDATION OF
A MACHINE LEARNING BASED VIRTUAL
BIOPSY SYSTEM IN KIDNEY TRANSPLANT
PATIENTS
Daniel Yoo, France
ML: My Svensson, Norway
WHAT HAPPENED TO BELATACEPT
20 FRI
59 ERA
TH
CONGRESS
PARIS & VIRTUAL
MAY 19-22, 202220
FRI
SCIENTIFIC PROGRAMME
HALL PLENARY 15:00-16:30 (CEST) HALL N01 15:00-16:30 (CEST) HALL N02 15:00-16:30 (CEST) HALL N03 15:00-16:30 (CEST)
Symposium 0.7 Symposium 3.2 Symposium 5.2 Symposium 4.4
JOINT SYMPOSIA ERA- SFNDT GENETICS PLUS X: ASSESSING QUALITY OF DRUG DISCOVERY AND
ARTIFICIAL INTELLIGENCE IN INNOVATION FROM DIALYSIS DELIVERY REPURPOSING
NEPHROLOGY COMBINING TECHNOLOGIES
Chairs: Edwina Brown, United Kingdom Chairs: Ziad Massy, France
Chairs: Maryvonne Hourmant, France Chairs: Albertien van Eerde, Netherlands Carlo Basile, Italy Lisbet Brandi, Denmark
Jadranka Buturovi -Ponikvar, Slovenia John Sayer, United Kingdom
1 Are we aware of the extent to which the 1 Drug repurposing: From kidney diseases
1 From the database to the clinic 1 Combining exome sequencing with reverse quality of dialysis depends on vascular to COVID-19
Alexandre Loupy, France phenotyping in steroid-resistant nephrotic access? Anna Greka, USA
syndrome Jose Ibeas, Spain
2 From the database to the clinic 2 RNA therapeutics for rare diseases:
Francesca Becherucci, Italy
Pierre-Antoine Gourraud, France hyperoxaluria and beyond
2 Engineering human tissues for studying Justine Bacchetta, France
3 Artificial intelligence in nephropathology
kidney disease, drug testing and
Vincent Vuiblet, France 2 Goal directed dialysis: individualising the 3 Metabolic Reprogramming and
replacement therapies.
4 Connected stools in nephrology prescription - can HD learn from PD? Reconstruction: Integration of Experimental
Christodoulos Xinaris, Cyprus
Patrick Jourdain, France Albert Power, United Kingdom and Computational Studies to Set the Path
3 Combining exome sequencing with Forward in ADPKD 23
3 Generic or individualised patient outcome
urinary metabolomics to unravel inborn Cristina Podrini, Italy
measures?
errors of metabolism.
Esmee M. van der Willik, Netherlands
Anna Köttgen, Germany
20 FRI
59 ERA
TH
CONGRESS
PARIS & VIRTUAL
MAY 19-22, 202220
FRI
SCIENTIFIC PROGRAMME
HALL N04 15:00-16:30 (CEST) HALL S01 15:00-16:30 (CEST) HALL S02 15:00-16:30 (CEST) HALL S03 15:00-16:30 (CEST)
Symposium 8.4 Free Communication Session 29 Free Communication Session 32 Free Communication Session 14
COVID, AKI AND BEYOND + Mini Lectures + Mini Lectures + Mini Lectures
Chairs: Nicholas Selby, United Kingdom KIDNEY GRAFT LOSS - IS IT METABOLIC KIDNEY INJURY RECENT ADVANCES IN THE
Maria Prendecki, United Kingdom INEVITABLE? Chairs: Laetitia Koppe, France TREATMENT OF IGAN
1 AKI during COVID-19 infection: specific Chairs: Lizia Peruzzi, Italy Marcin Adamczak, Poland Chairs: Rosanna Coppo, Italy
or non-specific renal injury? Dimitrios Goumenos, Greece ML: Jung Tak Park, South Korea Michel Jadoul, Belgium
Tobias Huber, Germany ML: Alica Debska Slizien, Poland BODY COMPOSITION AND KIDNEY ML: Rosanna Coppo, Italy
2 Brain changes in nephroCovid19 patients WHEN OBESITY IS A PROBLEM IN FUNCTION COMPLEMENT INHIBITION IN IGA
Davide Viggiano, Italy KIDNEY TRANSPLANT CANDIDATES AND NEPHROPATHY
RECIPIENTS?
3 Long-Covid and clincial implications NEFECON® (BUDESONIDE) IS AN
Judith Bruchfeld, Sweden GENE EXPRESSION PROFILES OF KIDNEY-SPECIFIC SILENCING OF NEAT1 EPIGENETIC MODIFIER IN IGA
PERITUBULAR CAPILLARITIS IN CHRONIC ALLEVIATES DIABETIC KIDNEY INJURY NEPHROPATHY
ANTIBODY-MEDIATED REJECTION Rui Xue Hong Kong, P.R. China Jasraj Bhachu, United Kingdom
Michael Eder, Austria
LIPID CHANGES AS EARLY INDICATOR NEFECON® SELECTIVELY MODIFIES
MICROVASCULAR INFLAMMATION IN FOR DIABETES INDUCED RENAL THE COMPOSITION OF CIRCULATING 24
KIDNEY TRANSPLANT BIOPSIES IN THE PATHOLOGY IMMUNE COMPLEXES IN IGA
ABSENCE OF HLA-DSA DISPLAYS INTENSE Rosalie Rietjens, Netherlands NEPHROPATHY
CYTOTOXIC T-CELL AND NK CELL BUT NOT Karen Molyneux, United Kingdom
THE COMBINATION OF EMPAGLIFLOZIN
PLASMA CELL INFILTRATION
AND ATRASENTAN ON TOP OF RAS ATACICEPT REDUCES SERUM ANTI-GD-
Anna Buxeda, Spain
BLOCKADE AMELIORATES CARDIORENAL IGA1 LEVELS IN IGAN PATIENTS
SURVIVAL BENEFIT OF PREEMPTIVE INJURY IN A TYPE 2 DIABETIC MOUSE Jonathan Barratt, United Kingdom
SIMULTANEOUS PANCREAS KIDNEY MODEL ATRASENTAN FOR THE TREATMENT OF
TRANSPLANTATION Ander Vergara Arana, Spain IGA NEPHROPATHY: INTERIM RESULTS
Enrique Montagud-Marrahi, Spain
ML: Mingyu Liang, USA FROM THE AFFINITY STUDY
A COMORBIDITY INDEX AND RENAL METABOLISM AND HYPERTENSION Muh Wong, Australia
PRETRANSPLANT PHYSICAL STATUS
PREDICT SURVIVAL IN OLDER KIDNEY
TRANSPLANT RECIPIENTS
Vasiliki Tsarpali, Norway
20 FRI
59 ERA
TH
CONGRESS
PARIS & VIRTUAL
MAY 19-22, 202220
FRI
SCIENTIFIC PROGRAMME
VIRTUAL HALL 1 15:00-16:30 (CEST) VIRTUAL HALL 2 15:00-16:30 (CEST) MINI ORAL HALL 16:30-17:00 (CEST) NEW
Symposium 2.2 Free Communication Session 1 SGLT2I IN CKD FISHBOWL
CHALLENGES IN PEDIATRIC + Mini Lectures SESSION
NEPHROLOGY RISK FACTORS IN CKD
Chairs: Peter Barany, Sweden Chairs: Orsolya Cseprekal, Hungary
Elena Levtchenko, Belgium Peter Stenvinkel, Sweden Chair:
Mario Cozzolino, Italy
1 Rewired: neurocognitive function in CKD ML: Lucia Del Vecchio, Italy
Jaap Groothoff, Netherlands OBESITY AS A HEALTH ISSUE: HOW
COVID 19 PANDEMICS AMPLIFIED IT AS A
2 Transition adolescent with CKD to adult
SCARING RISK FACTOR.
clinics
Panellists:
Gema Ariceta, Spain HUMORAL RESPONSE TO THIRD DOSE
OF SARS-COV-2 VACCINES IN THE CKD
SPECTRUM: THE SENCOVAC STUDY
Borja Quiroga, Spain Patrick Mark, United
Kingdom
3 Isotope diagnostics to improve CKD-MBD HUMORAL AND CELLULAR IMMUNE
management RESPONSES AFTER A THREE-DOSE 25
Rukshana Shroff, United Kingdom COURSE OF MRNA-1273 COVID-19
VACCINE IN KIDNEY TRANSPLANT
RECIPIENTS: A PROSPECTIVE COHORT
STUDY
David Cucchiari, Spain
Ionut Nistor, Romania
ASSOCIATION BETWEEN METABOLIC
DYSFUNCTION-ASSOCIATED FATTY
LIVER DISEASE AND HYPERFILTRATION
IN SUBJECTS WITH PREDIABETES AND
ABDOMINAL OBESITY WITHOUT EVIDENCE
OF CHRONIC KIDNEY DISEASE
Beatriz Fernandez
Aneliya Parvanova, Italy
Fernandez, Spain
ML: Peter Stenvinkel, Sweden
FOOD AS MEDICINE – CAN IT LINK THE
GUT MICROBIOTA TO AN IMPROVED
RENAL PHENOTYPE?
20 FRI
59 ERA
TH
CONGRESS
PARIS & VIRTUAL
MAY 19-22, 202220
FRI
SCIENTIFIC PROGRAMME
HALL PLENARY 17:00-18:30 (CEST) HALL N01 17:00-18:30 (CEST) HALL N02 17:00-18:30 (CEST) HALL N03 17:00-18:30 (CEST)
Symposium 0.2.1 Symposium 4.8 Symposium 1.2 Symposium 8.1
WHY NEPHROLOGY NEEDS PREVENTION OF CKD PLASTICITY OF RENAL CELLS UPCOMING INNOVATIONS IN
ADVANCED STATISTICAL PROGRESSION - NEWS IN THE Chairs: Sola Aoun Bahous, Lebanon ACUTE KIDNEY INJURY
METHODS TRADITIONAL RISK FACTORS Robert Fenton, Denmark Chairs: Thimoteus Speer, Germany
Chairs: Ivan Rychlik, Czech Republic Chairs: Tilman B. Drüeke, France 1 The plasticity of renin-producing cells Christiane Erley, Germany
Vivek Jha, India Marie Evans, Sweden Armin Kurtz, Germany 1 Deciphering the molecular mechanisms
1 Target Trial Emulation: Implications for 1 Diabetic kidney disease - early detection 2 The different facets of Myofibroblasts of necroinflammation in acute tubular
outcome studies on timing of dialysis and subsequent intervention for delaying in kidney necrosis
initiation the progression Rafael Kramann, Germany Wulf Tonnus, Germany
Edouard Fu, Netherlands Goce Spasovski, Republic of North
3 Proximal tubule dysfunction in Glycogen 2 What is to come in the next KDIGO AKI
Macedonia
2 Target Trial Emulation: Implications for Storage Disease guideline?
2 Acute Kidney Injury in Patients with
ETHICS ERAC YNP
transplant survival studies European
Renal Association Curatorium Young Nephrologists’ Platform
Francesco Trepiccione, Italy Marlies Ostermann, United Kingdom
Vianda Stel, Netherlands REGISTRY NPPC ERBP
Chronic Kidney Disease: is an adequate
3 Identifying patients at risk of the AKI-to-
Nephrology
European Renal Best Practice
and Public Policy Committee
GNC SAB ECC
prevention possible?
3 Joint Models – Applications in nephrology
ETHICS ERAC YNP
Green Nephrology Committee Scientific Advisory Board European
Electronic
Communication Committee
CKD transition
Mustafa Arici, Turkey
Renal Association Curatorium Young Nephrologists’ Platform
Nick Chesnaye, Netherlands REGISTRY NPPC
Nephrology
and Public Policy Committee
ERBP
European Renal Best Practice Morgan Grams, USA 26
GNC SAB ECC
Electronic
3 Prevention of CKD progression - news in
the traditional risk factors
Green Nephrology Committee Scientific Advisory Board Communication Committee
Francesca Mallamaci, Italy
20 FRI
59 ERA
TH
CONGRESS
PARIS & VIRTUAL
MAY 19-22, 202220
FRI
SCIENTIFIC PROGRAMME
HALL N04 17:00-18:30 (CEST) HALL S01 17:00-18:30 (CEST) HALL S02 17:00-18:30 (CEST) HALL S03 17:00-18:30 (CEST)
Free Communication Session Free Communication Session 5 Free Communication Session Free Communication Session
30 + Mini Lectures + Mini Lectures 15 + Mini Lectures 16 + Mini Lectures
CLINICAL OUTCOMES IN PATHOPHYSIOLOGY OF THE NEW ADVANCES IN LUPUS NEW INSIGHTS FROM CLINICAL
TRANSPLANTATION GLOMERULUS NEPHROPATHY TRIALS IN ANCA-ASSOCIATED
Chairs: Ewa Pawlowicz, Poland Chairs: Tobias Huber, Germany Chairs: Iva Gunnarsson, Sweden VASCULITIS
Peter Barany, Sweden Paola Romagnani, Italy Liz Lightstone, United Kingdom Chairs: Elena Zakarova, Russia,
ML: Miroslaw Wielgos, Poland ML: Anna Lervolino, Italy ML: Hans-Joachim Anders, Germany Annette Bruchfeld, Sweden
FERTILITY PROBLEMS IN KIDNEY ZEBRAFISH LARVAE TO STUDY AND TREAT A FAREWELL TO THE CONCEPT OF ML: Elena Csernok, Germany
TRANSPLANT RECIPIENTS MALE OB/GYN GLOMERULAR DISEASES INDUCTION AND MAINTENANCE ASSAYS FOR ANTI-GBM ANTIBODIES AND
THERAPY IN LUPUS NEPHRITIS DETECTION PROBLEMS
HLA-SPECIFIC MEMORY B CELLS AND TARGET DECONVOLUTION FROM
PATERNAL HLA MOLECULAR MISMATCH PHENOTYPIC SCREENS – IDENTIFICATION WEANING OF MAINTENANCE INCIDENCE OF INFECTIONS IN THE
IN FEMALE TRANSPLANT CANDIDATES OF ATAXIA TELANGIECTASIA MUTATED AS IMMUNOSUPPRESSIVE THERAPY IN LUPUS AVACOPAN GROUP VERSUS PREDNISONE
SENSITIZED BY PREGNANCY A POTENTIAL THERAPEUTIC TARGET FOR NEPHRITIS (WIN-LUPUS): A MULTICENTER GROUP IN ANCA-ASSOCIATED
Sara Sanz-Ureña, Spain PODOCYTE PROTECTION RANDOMIZED CONTROLLED TRIAL. VASCULITIS, RESULTS FROM THE PHASE 3
Jürgen Stumm, Germany Noemie Jourde-Chiche, France ADVOCATE STUDY 27
DEVELOPMENT AND VALIDATION OF
AN INTEGRATIVE DD-CFDNA SYSTEM HIGH SALT ENVIRONMENT DISRUPTS THE VOCLOSPORIN FOR LUPUS NEPHRITIS: Michael George, USA
TO PREDICT ALLOGRAFT REJECTION: A REGULATORY EFFECT OF PODOCIN ON RESULTS OF THE TWO-YEAR AURORA 2 LONG-TERM RENAL SURVIVAL OF
POPULATION BASED STUDY THE NEPHRIN-NEPHRIN DISTANCE CONTINUATION STUDY ANCA-ASSOCIATED VASCULITIS PATIENTS
Olivier Aubert, France Violetta Antal-Kónya, Hungary Y.K.O. Teng, Netherlands INCLUDED IN THE EUVAS RANDOMIZED
MONOCLONAL GAMMOPATHY IN NEPHROTOXICITY OF ANTIANGIOGENIC EFFECT OF ATACICEPT ON RENAL CLINICAL TRIALS
KIDNEY TRANSPLANTED PATIENTS: NOVEL THERAPIES: DIRECT IMPACT OF SORAFENIB FUNCTION IN SLE PATIENTS Beatriz Sanchez Alamo, Spain
INSIGHTS INTO LONG-TERM OUTCOMES ON THE PODOCYTE VIA GSK3B David Isenberg, United Kingdom CARDIOVASCULAR OUTCOMES
Marie-Sophie Meuleman, France Margaux Van Wynsberghe, France IN ANTI-NEUTROPHIL CYTOPLASMIC
EARLY REDUCTIONS IN PROTEINURIA
LONG-TERM OUTCOMES IN ECULIZUMAB- ADAPTIVE REMODELING OF MESANGIAL WITH VOCLOSPORIN TREATMENT ACROSS ANTIBODY ASSOCIATED VASCULITIS IN
TREATED KIDNEY TRANSPLANT PATIENTS EXTRACELLULAR MATRIX PROTEOGLYCAN LUPUS NEPHRITIS BIOPSY CLASSES: DENMARK 1996-2018
ENROLLED IN THE GLOBAL ATYPICAL COMPOSITION DURING IGA POOLED DATA FROM THE AURA-LV AND Louis Nygaard Pedersen, Denmark
HAEMOLYTIC URAEMIC SYNDROME NEPHROPATHY AURORA 1 TRIALS MALIGNANCIES IN PATIENTS WITH
REGISTRY Alva Johansson, Sweden Anca Askanase, United States Minor ANCA-ASSOCIATED VASCULITIS TREATED
Maria Gema Ariceta Iraola, Spain Outlying Islands WITHIN THE EUVAS TRIALS
Beatriz Sanchez Alamo, Spain
20 FRI
59 ERA
TH
CONGRESS
PARIS & VIRTUAL
MAY 19-22, 202220
FRI
SCIENTIFIC PROGRAMME
VIRTUAL HALL 1 17:00-18:30 (CEST) VIRTUAL HALL 2 17:00-18:30 (CEST)
Symposium 0.3 Free Communication Session
ASN HIGHLIGHTS 25 + Mini Lectures
FRAILTY AND DIALYSIS
COMPLICATIONS
Chairs: Blankestijn, Peter J., Netherlands
Chairs: Karin True, USA Ekart Robert, Slovenia
Patrick H. Nachman, USA
ML: Andrew Nixon, United Kingdom
1 AKI EMBEDDING NEEDS OF OLDER PEOPLE
Anitha Vijayanm, USA INTO ROUTINE MANAGEMENT OF
2 General Nephrology and CKD ESKD
Delphine S. Tuot, USA THE RELATIONSHIP BETWEEN
3 Hypertension CEREBROVASCULAR REACTIVITY AND
Tara I. Chang, USA INTRADIALYTIC CEREBRAL PERFUSION
Dawn Wolfgram, USA
SYMPTOM BURDEN AND INDIVIDUAL 28
SYMPTOMS BEFORE AND AFTER DIALYSIS
INITIATION IN OLDER PATIENTS
Esther De Rooij, Netherlands
FRAX IS USEFUL TOOL FOR PREDICTING
ALL-CAUSE MORTALITY IN ADDITION
TO THE RISK OF FRAGILE FRACTURE IN
HEMODIALYSIS PATIENTS
Takayuki, Fujii Japan
DEVELOPMENT AND VALIDATION OF
AN AI-BASED TRIAGE ALGORITHM
FOR INTENSIFIED PREVENTION OF
INTRADIALYTIC HYPOTENSION.
Federica Gervasoni, Italy
20 FRI
59 ERA
TH
CONGRESS
PARIS & VIRTUAL
MAY 19-22, 2022Join the
ERA Community
Discover the Membership
benefits at the ERA booth
www.era-online.org21 59 ERA
TH
DAY AT A CONGRESS
GLANCE PARIS & VIRTUAL
SAT MAY 19-22, 2022
INNOVATIVE TECHNOLOGIES PROVIDING INNOVATIVE INSIGHTS: KIDNEY
CONTENT & REMODELLING UPON INJURY
33
DAILY INDEX
EXPANSION OF HOME THERAPIES IN EUROPE: DESIRABLE AND POSSIBLE? 33
2021 PEARLS OF NDT AND CKJ 33
PHOSPHATE IN CKD FROM BENCH TO BEDSISDE 33
SCIENTIFIC PROGRAMME
BRIDGING THE GAP BETWEEN GENETICS AND NEPHROLOGY WORLDS:
34
LET'S ALL BECOME NEPHROGENETICISTS
THURSDAY - MAY 19, 2022 6
PHYSIOLOGY OF PODOCYTES: CLINICAL IMPLICATIONS 34
30
AKI MECHANISMS FROM PROMOTERS TO INHIBITORS 34
FRIDAY - MAY 20, 2022 13 CLINICAL OUTCOMES IN DIABETIC KIDNEY DISEASE AND CV
34
COMPLICATIONS
CKD IN EUROPE, THE VOICE OF THE PATIENTS 35
SATURDAY - MAY 21, 2022 30
ERA GENERAL ASSEMBLY 35
SCREENING FOR EARLY CKD - THE IMPORTANCE FOR CARDIOVASCULAR
35
SUNDAY - MAY 22, 2022 47 RISK MANAGEMENT
BIOELECTRONIC MEDICINE, HYPERTENSION AND INFLAMMATION 36
CACHEXIA OR PROTEIN ENERGY WASTING: WHAT IS NEW IN CKD? 36
THE CONNECT PROJECT: COGNITIVE DECLINE IN NEPHRO-NEUROLOGY:
37
EUROPEAN COOPERATIVE TARGET
ONCONEPHROLOGY 37
ANCA-ASSOCIATED KIDNEY VASCULITIS ACROSS LIFETIME 3721 59 ERA
TH
DAY AT A CONGRESS
GLANCE PARIS & VIRTUAL
SAT MAY 19-22, 2022
PERSONALISED MEDICINE 37
CONTENT & CV COMPLICATIONS IN DIALYSIS 38
DAILY INDEX PATIENT-REPORTED OUTCOME MEASURES - DOES IT IMPROVE HEALTH-
CARE?
38
PREDICTORS OF OUTCOME IN ANCA-ASSOCIATED VASCULITIS 38
SCIENTIFIC PROGRAMME
NEW TRENDS IN CKD 38
THURSDAY - MAY 19, 2022 6 TREATMENT FOR CKD 39
A FAREWELL TO HYPERTENSIVE NEPHROSCLEROSIS 40 31
FRIDAY - MAY 20, 2022 13 CHOICE OF KRT 40
NEW AVENUES IN LUPUS NEPHRITIS 40
SATURDAY - MAY 21, 2022 30 IS MICROBIOTA RESPONSIBLE FOR THE UREMIC TOXICITY? 40
TUBULAR TRANSPORT 41
SUNDAY - MAY 22, 2022 47 CLINICAL ASPECTS OF AKI PREVENTION AND TREATMENT 41
GENETIC SCREENING FOR CHRONIC KIDNEY DISEASE 41
RENOPROTECTIVE DRUGS IN KIDNEY TRANSPLANTATION - READY FOR
41
PRIME TIME?
NEPHROTIC SYNDROME FROM CHILDHOOD TO ADULTHOOD 42
COVID-19 AND OXYGEN 4221 59 ERA
TH
DAY AT A CONGRESS
GLANCE PARIS & VIRTUAL
SAT MAY 19-22, 2022
CKD-MBD IN ESKD – TRADITIONAL AND NOVEL APPROACHES 43
CONTENT & IMMUNOCOMPETENCE IN RENAL TRANSPLANTATION 43
DAILY INDEX BRIDGING THE GAPS BETWEEN BASIC SCIENCE AND HUMAN TRIALS FOR
KIDNEY HEALTH INTERVENTIONS
43
HOW TO OPTIMALLY PREVENT PROGRESSION IN ADPKD 43
SCIENTIFIC PROGRAMME
AKI-CKD TRANSITION - IS IT INEVITABLE? 44
THURSDAY - MAY 19, 2022 6 HUMAN URINE AS THE WINDOW OF RENAL DISEASE 44
VARIOUS ASPECTS OF CELL BIOLOGY & METABOLISM I 44 32
FRIDAY - MAY 20, 2022 13 GENE AND CELL THERAPY COME OF AGE FOR THE NEPHROLOGIST 44
SEX DIFFERENCES IN NEPHROLOGY - DOES IT MATTER FOR PATIENT
45
OUTCOME?
SATURDAY - MAY 21, 2022 30 PEDIATRIC NEPHROLOGY 45
SUNDAY - MAY 22, 2022 4721
SAT
SCIENTIFIC PROGRAMME
HALL N01 08:00-09:30 (CEST) HALL N02 08:00-09:30 (CEST) HALL N03 08:00-09:30 (CEST) HALL N04 08:00-09:30 (CEST)
Symposium 3.4 Symposium 5.3 Symposium 0.4 Symposium 4.6
INNOVATIVE TECHNOLOGIES EXPANSION OF HOME 2021 PEARLS OF NDT AND CKJ PHOSPHATE IN CKD FROM
PROVIDING INNOVATIVE THERAPIES IN EUROPE: BENCH TO BEDSISDE
Chairs: Denis Fouque, France
INSIGHTS: KIDNEY DESIRABLE AND POSSIBLE?
Maria José Soler, Spain Chairs: Amaryllis Van Craenenbroeck,
REMODELLING UPON INJURY
Chairs: Nicola Matthews, Canada 1 NDT Belgium
Chairs: Martin De Borst, Netherlands Tamara Jemcov, Serbia Marlies Ostermann, United Kingdom Juan Jesus Carrero, Sweden
Beatriz Sanchez Alamo, Spain 1 Why does use of home therapies vary Hans-Joachim Anders, Germany 1 Consequences of phosphate meeting
1 Single cell RNA sequencing of the human across Europe? 2 CKJ cholesterol
kidney: Identifying new drug targets for Maria Slon Roblero, Spain Roser Torra, Spain Xiong Z. Ruan, United Kingdom
kidney fibrosis. 2 Variability of home therapies use in UK Will Herrington, United Kingdom 2 Targeting NaPi-IIb for hyperphosphatemia
Christian Kuppe, Germany units: early results from the Inter-CEPt study in CKD Patients - The Dead End?
2 Clonal lineage tracing: The glomerular Simon Davies, United Kingdom Mugurel Apetrii, Romania
crescent in RPGN is a monoclonal lesion 3 Does access to assisted PD increase use 3 Intestinal phosphate binders to reduce
that responds to clone-directed therapy of PD cardiovascular risk in patients with CKD?
Paola Romagnani, Italy Anita van Eck van der Sluijs, Nigel Toussaint, Australia 33
3 Tissue proteomics to monitor stress Netherlands
responses in the kidney
Markus Rinschen, Denmark
21 SAT
59 ERA
TH
CONGRESS
PARIS & VIRTUAL
MAY 19-22, 202221
SAT
SCIENTIFIC PROGRAMME
HALL S01 08:00-09:30 (CEST) HALL S02 08:00-09:30 (CEST) HALL S03 08:00-09:30 (CEST) VIRTUAL HALL 1 08:00-09:30 (CEST)
Symposium 2.4 Symposium 1.4 Free Communication Session 35 Free Communication Session 33 +
BRIDGING THE GAP BETWEEN PHYSIOLOGY OF PODOCYTES: + Mini Lectures Mini Lectures
GENETICS AND NEPHROLOGY CLINICAL IMPLICATIONS AKI MECHANISMS FROM CLINICAL OUTCOMES IN DIABETIC
WORLDS: LET'S ALL BECOME Chairs: Rachel Lennon, United Kingdom PROMOTERS TO INHIBITORS KIDNEY DISEASE AND CV
NEPHROGENETICISTS Marc Vervloet, Netherlands Chairs: Clara García-Carro, Spain COMPLICATIONS
Chairs: Rukshana Shroff, United Kingdom 1 Super-resolution microscopy meets kidney Andrzej Jan Wiecek, Poland Chairs: Lucia Del Vecchio, Italy
Franz Schaefer, Germany research and diagnosis ML: Mehmet Kanbay, Turkey Peter Rossing, Denmark
1 How the genomics England consortium Nicole Endlich, Germany SGLT2 INHIBITORS AND AKI OF CANAGLIFLOZIN ON
changed nephrogenetics in England. 2 Vitamin D3 influences the differentiation of KINETICS OF RENAL INJURY AFTER CARDIOVASCULAR AND KIDNEY EVENTS IN
Daniel Gale, United Kingdom podocytes in situ and in vitro RHABDOMYOLYSIS: IMPLICATION PATIENTS WITH CHRONIC KIDNEY DISEASE
Tim Lange, Germany OF INNATE IMMUNE CELLS AND WITH AND WITHOUT PERIPHERAL VASCULAR
2 Genetic-first approaches in ESKD of
COMPLEMENT ACTIVATION DISEASE: INTEGRATED ANALYSIS FROM THE
unknown significance 3 Podocyte lipid metabolism
Anne Grunenwald, France CANVAS PROGRAM AND CREDENCE TRIAL
Laurent Mesnard, France Catherine Meyer-Schwesinger, Germany Adeera Levin, Canada
3 What about the kids: practical aspects of KIDNEY INJURY MOLECULE-1-
MEDIATED SMALL EXTRACELLULAR BASELINE CHARACTERISTICS OF THE FLOW 34
care for children at risk of genetic disease
VESICLES UPTAKE IS CRUCIAL FOR RENAL TRIAL POPULATION: KIDNEY OUTCOMES
that all adult nephrologists should know.
TUBULOINTERSTITIAL INFLAMMATION TRIAL WITH ONCE-WEEKLY SEMAGLUTIDE IN
Mekahli Djalila, Belgium
Jun Chen, P.R. China PEOPLE WITH TYPE 2 DIABETES AND CHRONIC
KIDNEY DISEASE
DEFICIENCY OF PROXIMAL TUBULAR Vlado Perkovic, Australia
CYCLIN-DEPENDENT KINASE 12
EXACERBATES KIDNEY INJURY THROUGH REAL-WORLD USE OF ONCE-WEEKLY
DNA-DAMAGE RESPONSE SEMAGLUTIDE BY BASELINE ESTIMATED
Yilin zhang, P.R. China GLOMERULAR FILTRATION RATE – A POST HOC
ANALYSIS OF POOLED DATA FROM THE SURE
STUDIES (CANADA, DENMARK/SWEDEN,
SWITZERLAND AND UNITED KINGDOM)
Gottfried Rudofsky, United Kingdom
COMPARATIVE EFFECTIVENESS OF
DIPEPTIDYL PEPTIDASE-4 INHIBITORS
VERSUS SULFONYLUREAS IN ADDITION TO
METFORMIN: A POPULATION-BASED COHORT
STUDY OF PATIENTS WITH DIABETES
Hon-Yen Wu Taiwan, R.O.C.
ASSOCIATION BETWEEN CIRCULATING
LEVELS OF 25-HYDROXYVITAMIN D AND
21 SAT
METALLOPROTEINASE-10 (MMP 10) IN
PATIENTS WITH TYPE 2 DIABETES MELLITUS.
59 ERA
TH
CROSS SECTIONAL STUDY.
Abasheva Daria, Spain
CONGRESS
PARIS & VIRTUAL
MAY 19-22, 202221
SAT
SCIENTIFIC PROGRAMME
VIRTUAL HALL 2 08:00-09:30 (CEST) HALL PLENARY 09:30-10:45 (CEST) ERA MEETING ROOM 1 13:30-14:30 (CEST)
Symposium 0.8 ERA GENERAL ASSEMBLY SCREENING FOR EARLY CKD - THE
CKD IN EUROPE, THE VOICE All ERA active members are invited to IMPORTANCE FOR CARDIOVASCULAR
OF THE PATIENTS participate in the ERA General Assembly. RISK MANAGEMENT
Chairs: Jan van Cruchten, Netherlands Members (and their status of FULL or Chairs: Alexander Rosenkranz, Austria
Lucile Mercadal, France ASSOCIATE) will be automatically Ronald Gansevoort, Netherlands
recognized by the system. Full members will 1 The importance of Real Word Evidence in Early
CKD in Europe: 100 million people with kidney
be able to vote (Associate members - cannot VOTE! Screening and Detection of CKD
disease
vote but they can ask questions). Navdeep Tangri, Canada
Raymond Vanholder, Belgium
Part I 09.30 - 09.40 2 The place of CKD in guidelines for Cardiovascular
The experience of patients in France during the
pandemic OPENING Risk Management
Christian Baudelot, France Welcome, Christoph Wanner (President) Nikolaus Marx, Germany
The role of patients and their associations in 1 Minutes of the 58th General Assembly, 3 One step beyond: towards population screening
crisis management Ivan Rychlik (Secretary-Treasurer) for CKD?
Yvanie Caillé, France Lyanne Kieneker, Netherlands
Part II 09.40 - 10.30
4 Raising awareness among physicians and the public 35
The role of patients and their associations in
2 Report from the President, Katharina Andrea Schütt, Germany
crisis management
Christoph Wanner
Anne Stinat, France
3 Report from the Secretary‐Treasurer,
Ivan Rychlik This symposium is organized by the European Renal
Association Curatorium (ERAC) honoring the recent
4 Report from the Renal Science Chair, start of several CKD screening and awareness programs
Danilo Fliser across Europe: Strong Kidneys, Guardians for Health,
5 Report from the Clinical Nephrology REVEAL CKD, INSIDE CKD, the Kidney Health Action
Governance Chair, Group, and the THOMAS study
Alberto Ortiz
ETHICS ERAC YNP
Part III 10.30 - 10.45 European
Renal Association Curatorium Young Nephrologists’ Platform
6 Election of the Ordinary Council Member
REGISTRY NPPC ERBP
(one vacancy), Nephrology
Christoph Wanner
European Renal Best Practice
and Public Policy Committee
7 Venue and date of the 2024 ERA GNC SAB ECC
Congress,
Electronic
Green Nephrology Committee Scientific Advisory Board Communication Committee
Christoph Wanner
8 Date and venue of the next General
Assembly,
21 SAT
Ivan Rychlik
59 ERA
TH
9 Any other business
FERA awards,
CONGRESS Ivan Rychlik
CLOSURE, Christoph Wanner
PARIS & VIRTUAL
MAY 19-22, 2022You can also read
